Keros Therapeutics Inc [NASDAQ: KROS] traded at a high on Thursday, posting a 0.96 gain after which it closed the day’ session at $10.52.
The results of the trading session contributed to over 3199865 shares changing hands. Over the past one week, the price volatility of Keros Therapeutics Inc stands at 8.73% while the volatility over the past one month is 6.61%.
The market cap for KROS stock reached $426.14 million, with 39.26 million shares outstanding and 32.86 million shares in the current float. Compared to the average trading volume of 1.19M shares, KROS reached a trading volume of 3199865 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Keros Therapeutics Inc [KROS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KROS shares is $39.55 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KROS stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Keros Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 16, 2024. The new note on the price target was released on December 16, 2024, representing the official price target for Keros Therapeutics Inc stock. Previously, the target price had yet another drop from $100 to $47, while H.C. Wainwright kept a Buy rating on KROS stock.
The Average True Range (ATR) for Keros Therapeutics Inc is set at 2.32, with the Price to Sales ratio for KROS stock in the period of the last 12 months amounting to 655.60. The Price to Book ratio for the last quarter was 0.78, with the Price to Cash per share for the same quarter was set at 13.10.
How has KROS stock performed recently?
Keros Therapeutics Inc [KROS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.35. With this latest performance, KROS shares dropped by -44.13% in over the last four-week period, additionally sinking by -78.85% over the last 6 months – not to mention a drop of -80.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KROS stock in for the last two-week period is set at 18.93, with the RSI for the last a single of trading hit 13.51, and the three-weeks RSI is set at 22.88 for Keros Therapeutics Inc [KROS]. The present Moving Average for the last 50 days of trading for this stock 40.52, while it was recorded at 12.16 for the last single week of trading, and 49.72 for the last 200 days.
Keros Therapeutics Inc [KROS]: Deeper insight into the fundamentals
Keros Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.03 and a Current Ratio set at 19.03.
Insider trade positions for Keros Therapeutics Inc [KROS]
There are presently around $100.44%, or 102.54%% of KROS stock, in the hands of institutional investors. The top three institutional holders of KROS stocks are: FMR LLC with ownership of 4.72 million shares, which is approximately 16.0279%. BLACKROCK INC., holding 2.51 million shares of the stock with an approximate value of $$114.86 million in KROS stocks shares; and BLACKROCK INC., currently with $$80.3 million in KROS stock with ownership which is approximately 5.967%.
